As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Corbus Pharmaceuticals Holdings, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 9.9%. 13 filings are on record since July 16, 2025 (Schedule 13G, September 30, 2026).
Who owns Corbus Pharmaceuticals Holdings, Inc.?
Sell to companies like Corbus Pharmaceuticals Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 1,500,000 · Sole dispositive: 0 · Shared dispositive: 1,500,000 · SCHEDULE 13G/A, 2026-11-02
- · Reporting person: Aberdeen Group plc · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-29
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 1,914,788 · Sole dispositive: 0 · Shared dispositive: 1,914,788 · SCHEDULE 13G, 2026-09-30
- · Reporting person: Citadel Advisors LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 1,081,182 · Shared voting: 0 · Sole dispositive: 1,093,434 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
Corbus Pharmaceuticals Holdings, Inc. has 13 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.9% | 1,914,788 | SCHEDULE 13G, 2026-09-30 | 2026-09-23 |
| Cormorant Asset Management, LP | 7.76% | 1,500,000 | SCHEDULE 13G/A, 2026-11-02 | 2026-10-31 |
| BlackRock, Inc. | 5.9% | 1,093,434 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| The Vanguard Group | 4.89% | 599,495 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| Citadel Securities LLC | 1.1% | 206,354 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Aberdeen Group plc | 0% | 0 | SCHEDULE 13G/A, 2026-10-29 | 2026-09-16 |
| Octagon Capital Advisors LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind Corbus Pharmaceuticals Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Corbus Pharmaceuticals Holdings, Inc. and the records around it.
Corbus Pharmaceuticals Holdings, Inc. elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
Watch Corbus Pharmaceuticals Holdings, Inc.
Get an email when Corbus Pharmaceuticals Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Corbus Pharmaceuticals Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Corbus Pharmaceuticals Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corbus Pharmaceuticals Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 1,914,788 | 0 | 1,914,788 | SCHEDULE 13G, 2026-09-30 |
| Peter Kolchinsky | 0 | 1,914,788 | 0 | 1,914,788 | SCHEDULE 13G, 2026-09-30 |
| Rajeev Shah | 0 | 1,914,788 | 0 | 1,914,788 | SCHEDULE 13G, 2026-09-30 |
| RA Capital Healthcare Fund, L.P. | 0 | 1,914,788 | 0 | 1,914,788 | SCHEDULE 13G, 2026-09-30 |
| Cormorant Asset Management, LP | 0 | 1,500,000 | 0 | 1,500,000 | SCHEDULE 13G/A, 2026-11-02 |
| Chen Bihua | 0 | 1,500,000 | 0 | 1,500,000 | SCHEDULE 13G/A, 2026-11-02 |
| BlackRock, Inc. | 1,081,182 | 0 | 1,093,434 | 0 | SCHEDULE 13G, 2026-07-27 |
| Citadel Advisors LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Advisors Holdings LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel GP LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities LLC | 0 | 206,354 | 0 | 206,354 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities Group LP | 0 | 206,354 | 0 | 206,354 | SCHEDULE 13G/A, 2026-08-14 |
| Citadel Securities GP LLC | 0 | 206,354 | 0 | 206,354 | SCHEDULE 13G/A, 2026-08-14 |
| Kenneth Griffin | 0 | 206,354 | 0 | 206,354 | SCHEDULE 13G/A, 2026-08-14 |
| Aberdeen Group plc | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-29 |
| abrdn Inc. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-29 |
| Octagon Capital Advisors LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Octagon Investments Master Fund LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Ting Jia | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-14 |
The latest filing identifies Corbus Pharmaceuticals Holdings, Inc. by CUSIP 21833P301 and gives its principal executive office as 500 River Ridge Drive, Norwood, MA 02062 (SCHEDULE 13G/A, 2026-11-02).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-09-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2.9% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 4.89% | SCHEDULE 13G/A |
| 2025-11-12 | Kenneth Griffin | 5.3% | SCHEDULE 13G |
| 2025-11-14 | Cormorant Asset Management, LP | 12.82% | SCHEDULE 13G/A |
| 2025-12-15 | Cormorant Asset Management, LP | 13.36% | SCHEDULE 13G/A |
| 2026-01-16 | Aberdeen Group plc | 7.53% | SCHEDULE 13G |
| 2026-02-10 | Octagon Capital Advisors LP | 5.4% | SCHEDULE 13G/A |
| 2026-05-14 | Octagon Capital Advisors LP | 0% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 5.9% | SCHEDULE 13G |
| 2026-08-14 | Citadel Securities LLC | 1.1% | SCHEDULE 13G/A |
| 2026-09-30 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-10-29 | Aberdeen Group plc | 0% | SCHEDULE 13G/A |
| 2026-11-02 | Cormorant Asset Management, LP | 7.76% | SCHEDULE 13G/A |
Questions about who owns Corbus Pharmaceuticals Holdings, Inc.
Who owns Corbus Pharmaceuticals Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Corbus Pharmaceuticals Holdings, Inc.: RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-09-30), Cormorant Asset Management, LP (7.76%, Schedule 13G/A, filed 2026-11-02) and BlackRock, Inc. (5.9%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Corbus Pharmaceuticals Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Corbus Pharmaceuticals Holdings, Inc. on this page are RA Capital Management, L.P. (9.9%), Cormorant Asset Management, LP (7.76%) and BlackRock, Inc. (5.9%).
When did RA Capital Management, L.P. buy into Corbus Pharmaceuticals Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G, filed 2026-09-30, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Corbus Pharmaceuticals Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Leadership change: Brent Pfeiffenberger appointed, Director | — | Leadership changes | Source |
| April 7, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Corbus Pharmaceuticals Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.